下咽癌诱导化疗：DNA 修复基因多态性的影响。
Induction Chemotherapy in Hypopharyngeal Cancer: Influence of DNA Repair Gene Polymorphisms.
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
出版信息
Anticancer Res. 2020 Jun;40(6):3277-3285. doi: 10.21873/anticanres.14310.
BACKGROUND/AIM: The aim was to clarify whether DNA repair gene polymorphisms can be used to predict response to cisplatin, 5-fluorouracil, and docetaxel (TPF) as induction chemotherapy (ICT) in Japanese patients with hypopharyngeal cancer (HPC).
MATERIALS AND METHODS
DNA repair gene polymorphisms (rs3212986, rs1799793, rs13181, and rs25487) were analyzed in 117 HPC patients and 125 control subjects by PCR-restriction fragment length polymorphism. Forty-one HPC patients who received TPF-based ICT, followed by surgery or chemoradiotherapy/radiotherapy were analyzed for ICT response, laryngeal preservation, and survival outcome.
RESULTS
ICT responders (29 cases) had significantly better overall survival than ICT non-responders (12 cases; 86.0% vs. 37.0%, respectively, p<0.01 by log-rank test) and better laryngeal preservation rates. The DNA repair gene polymorphisms were not related to ICT response.
CONCLUSION
ICT is beneficial for chemoselection of HPC patients, but a role for DNA repair gene polymorphisms in ICT response was not confirmed.
背景/目的：本研究旨在阐明 DNA 修复基因多态性是否可用于预测日本下咽癌（HPC）患者对顺铂、5-氟尿嘧啶和多西他赛（TPF）作为诱导化疗（ICT）的反应。
材料和方法
通过 PCR-限制性片段长度多态性分析了 117 例 HPC 患者和 125 例对照者的 DNA 修复基因多态性（rs3212986、rs1799793、rs13181 和 rs25487）。对接受 TPF 为基础的 ICT 后行手术或放化疗/放疗的 41 例 HPC 患者进行了 ICT 反应、喉保留和生存结局分析。
结果
ICT 应答者（29 例）的总生存率明显优于 ICT 无应答者（12 例；分别为 86.0%和 37.0%，对数秩检验，p<0.01），且喉保留率更高。DNA 修复基因多态性与 ICT 反应无关。
结论
ICT 有利于 HPC 患者的化疗选择，但 DNA 修复基因多态性在 ICT 反应中的作用尚未得到证实。
Zotero 插件